Author

E. Bunyan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:flow cytometry· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

T. Cihlar· 2 shared A. Ambrosi· 1 shared A. Birukova· 1 shared A. Davie· 1 shared A. Niedziela-Majka· 1 shared A. Schaefer· 1 shared A. T. Vose· 1 shared A. V. Misharin· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

T. Cihlar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tissue-resident alveolar macrophages reduce O3-induced inflammation via MerTK mediated efferocytosis

M. A. Guttenberg, A. T. Vose, A. Birukova, K. Lewars, R. I. Cumming, M. C. Albright, J. I. Mark, C. J. Salazar, S. Swaminathan, Z. Yu, Y. V. Sokolenko, E. Bunyan, M. J. Yaeger, M. B. Fessler, L. G. Que, , R. M. Tighe

This study shows tissue-resident alveolar macrophages reduce O3-induced inflammation by clearing apoptotic cells via MerTK-mediated efferocytosis in mice and humans.

bioRxiv · Nov 6, 2023 · PreprintImmunology

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys

R. L. Mackman, R. Kalla, D. Babusis, J. Pitts, K. T. Barrett, K. Chun, V. Du Pont, L. Rodriguez, J. Moshiri, Y. Xu, M. Lee, G. Lee, B. Bleier, A.-Q. Nguyen, B. M. O'Keefe, , T. Cihlar

bioRxiv · Apr 28, 2023Pharmacology & Toxicology

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

D. Martinez, A. Schaefer, S. R. Leist, D. Li, K. Gully, J. Feng, E. Bunyan, D. Porter, T. Cihlar, S. Montgomery, B. Haynes, R. S. Baric, M. C. Nussenzweig, T. P. Sheahan

This study evaluates combination therapies of remdesivir and monoclonal antibodies for SARS-CoV-2 and its B.1.351 variant in mice, showing improved outcomes with the antibody combination.

bioRxiv · Jan 27, 2021Microbiology